Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 11/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55448 | 0.84 | PIK3CA (0.53) | PDE2APIK3CAMTORHRH1HRH4 | |
| SCHEMBL55406 | 0.80 | MTOR (0.53) | PIK3CAMTOR | |
| SCHEMBL24955621 | 0.79 | PDE2A (0.46) | PDE2APIK3CAMTORHRH1HRH4 | |
| SCHEMBL31106958 | 0.79 | PDE2A (0.46) | PDE2APIK3CAMTORHRH1HRH4 | |
| SCHEMBL55439 | 0.73 | PIK3CA (0.79) | PIK3CAMTOR | |
| SCHEMBL12264967 | 0.72 | KMT2A (0.62) | PDE2APIK3CAHRH1HRH4KMT2A | |
| SCHEMBL2192881 | 0.72 | HRH1 (0.66) | PDE2AHRH1HRH4KMT2AGAA | |
| SCHEMBL55865 | 0.70 | PIK3CA (0.66) | PIK3CAMTOR | |
| SCHEMBL30202116 | 0.69 | PDE2A (0.46) | PDE2AHRH1HRH4KMT2AGAA | |
| SCHEMBL24956785 | 0.69 | PDE2A (0.46) | PDE2AHRH1HRH4KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | PDE2A 1484/4885PIK3CA 2/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.